Biogen's tau drug diranersen shows a larger benefit at two years at CTAD as Acadia's Alzheimer's psychosis drug narrowly misses
Biogen's diranersen showed a 38% slower decline in Alzheimer's patients at two years, per open-label extension data. Acadia's remlifanserin missed primary endpoint in Alzheimer's psychosis trial. Eisai and Biogen reported Leqembi's five-year data showing reduced decline.
How this was made
The 30-second read
Why it matters
These disclosures represent the first public release of the two‑year data, providing fresh material for traders.
Market read
First‑time release of longer‑term Alzheimer’s trial data, likely to move the involved stocks and the neuro‑degeneration sector.
What to watch
The small sample size (60 patients) and lack of a re‑randomized control limit the robustness of the efficacy claim.
Background
The article summarizes late‑breaking clinical trial updates presented at the CTAD conference, covering Biogen, Acadia and Eisai.
Ticker impact
Biogen presented new two‑year Phase 2 data for its tau‑lowering drug diranersen showing a 38% slower decline at week 96.
likely upward pressure as investors price in improved efficacy signals
Phase 2 data are the first indication of meaningful clinical benefit; markets typically reward such news for biotech stocks.
Acadia reported that its psychosis drug remlifanserin missed the primary endpoint by 2.2 points at week 6.
potential downside as the primary endpoint was not met
Missing a primary endpoint in a Phase 2 trial is a material negative for a small‑cap biotech.
Market effects
Positive signals for tau‑targeting therapeutics could lift the broader neuro‑degeneration biotech sector.
U.S. biotech indices may see modest gains; Japanese pharma index could benefit from Eisai’s data.
The data add to the growing pipeline narrative for Alzheimer’s treatments worldwide.
Counterpoint
Investors may remain cautious, noting that the two‑year benefit stems from an open‑label extension rather than a blinded comparison.
Key entities
- CompanyBiogen
US biotech developing tau‑lowering therapy diranersen.
- CompanyAcadia Pharmaceuticals
US biotech developing remlifanserin for Alzheimer’s psychosis.
- CompanyEisai
Japanese pharma co‑developer of lecanemab (Leqembi).



